Medexus Pharmaceuticals Stock Net Asset
| MDP Stock | 2.87 0.02 0.70% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Medexus Pharmaceuticals' long-term financial health and intrinsic value.
Medexus | Net Asset |
Medexus Pharmaceuticals Company Net Asset Analysis
Medexus Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Medexus Pharmaceuticals Net Asset | 171.84 M |
Most of Medexus Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medexus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medexus Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Medexus Pharmaceuticals is extremely important. It helps to project a fair market value of Medexus Stock properly, considering its historical fundamentals such as Net Asset. Since Medexus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medexus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medexus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Medexus Total Assets
Total Assets |
|
Based on the recorded statements, Medexus Pharmaceuticals has a Net Asset of 171.84 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all Canada stocks is notably lower than that of the firm.
Medexus Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medexus Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medexus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Medexus Pharmaceuticals by comparing valuation metrics of similar companies.Medexus Pharmaceuticals is currently under evaluation in net asset category among its peers.
Medexus Fundamentals
| Return On Equity | 0.0188 | ||||
| Return On Asset | 0.0351 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 110.05 M | ||||
| Shares Outstanding | 32.26 M | ||||
| Shares Owned By Insiders | 7.24 % | ||||
| Shares Owned By Institutions | 3.29 % | ||||
| Number Of Shares Shorted | 5.27 K | ||||
| Price To Book | 1.26 X | ||||
| Price To Sales | 0.88 X | ||||
| Revenue | 108.33 M | ||||
| Gross Profit | 63.45 M | ||||
| EBITDA | 16.48 M | ||||
| Net Income | 2.25 M | ||||
| Cash And Equivalents | 23.97 M | ||||
| Total Debt | 36.98 M | ||||
| Book Value Per Share | 1.64 X | ||||
| Cash Flow From Operations | 24.03 M | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | 0.03 X | ||||
| Target Price | 6.71 | ||||
| Number Of Employees | 91 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 92.58 M | ||||
| Total Asset | 171.84 M | ||||
| Retained Earnings | (61.99 M) | ||||
| Working Capital | (16.74 M) | ||||
| Net Asset | 171.84 M |
About Medexus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medexus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medexus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medexus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Medexus Stock
| 0.57 | GOOG | Alphabet CDR | PairCorr |
| 0.57 | GOOG | Alphabet CDR | PairCorr |
| 0.43 | AAPL | Apple Inc CDR | PairCorr |
| 0.43 | AAPL | Apple CDR | PairCorr |
| 0.41 | NVDA | NVIDIA CDR | PairCorr |
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.